Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICPIs) are novel therapeutic agents targeting a variety of cancers by enhanced T cell activation. Immune-related adverse events (irAEs) commonly occur with ICPI use and can affect multiple organ systems including the gastrointestinal tract. Due to irAEs, the use of ICPI...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Jean R., Davis, Amy D., Rodriguez, Eduardo A., Vela, Marcelo F., Heigh, Russell I., Salomao, Marcela A., Gurudu, Suryakanth R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323374/
https://www.ncbi.nlm.nih.gov/pubmed/30631256
http://dx.doi.org/10.1159/000493183
_version_ 1783385752321654784
author Kuo, Jean R.
Davis, Amy D.
Rodriguez, Eduardo A.
Vela, Marcelo F.
Heigh, Russell I.
Salomao, Marcela A.
Gurudu, Suryakanth R.
author_facet Kuo, Jean R.
Davis, Amy D.
Rodriguez, Eduardo A.
Vela, Marcelo F.
Heigh, Russell I.
Salomao, Marcela A.
Gurudu, Suryakanth R.
author_sort Kuo, Jean R.
collection PubMed
description Immune checkpoint inhibitors (ICPIs) are novel therapeutic agents targeting a variety of cancers by enhanced T cell activation. Immune-related adverse events (irAEs) commonly occur with ICPI use and can affect multiple organ systems including the gastrointestinal tract. Due to irAEs, the use of ICPIs is limited in autoimmune diseases. We present a case of microscopic colitis diagnosed after the initiation of nivolumab and a case of ipilimumab colitis and Clostridium difficile in the setting of Crohn's colitis.
format Online
Article
Text
id pubmed-6323374
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-63233742019-01-10 Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors Kuo, Jean R. Davis, Amy D. Rodriguez, Eduardo A. Vela, Marcelo F. Heigh, Russell I. Salomao, Marcela A. Gurudu, Suryakanth R. Case Rep Gastroenterol Case Series Immune checkpoint inhibitors (ICPIs) are novel therapeutic agents targeting a variety of cancers by enhanced T cell activation. Immune-related adverse events (irAEs) commonly occur with ICPI use and can affect multiple organ systems including the gastrointestinal tract. Due to irAEs, the use of ICPIs is limited in autoimmune diseases. We present a case of microscopic colitis diagnosed after the initiation of nivolumab and a case of ipilimumab colitis and Clostridium difficile in the setting of Crohn's colitis. S. Karger AG 2018-11-28 /pmc/articles/PMC6323374/ /pubmed/30631256 http://dx.doi.org/10.1159/000493183 Text en Copyright © 2018 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Series
Kuo, Jean R.
Davis, Amy D.
Rodriguez, Eduardo A.
Vela, Marcelo F.
Heigh, Russell I.
Salomao, Marcela A.
Gurudu, Suryakanth R.
Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors
title Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors
title_full Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors
title_fullStr Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors
title_full_unstemmed Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors
title_short Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors
title_sort severe diarrhea in the setting of immune checkpoint inhibitors
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323374/
https://www.ncbi.nlm.nih.gov/pubmed/30631256
http://dx.doi.org/10.1159/000493183
work_keys_str_mv AT kuojeanr severediarrheainthesettingofimmunecheckpointinhibitors
AT davisamyd severediarrheainthesettingofimmunecheckpointinhibitors
AT rodriguezeduardoa severediarrheainthesettingofimmunecheckpointinhibitors
AT velamarcelof severediarrheainthesettingofimmunecheckpointinhibitors
AT heighrusselli severediarrheainthesettingofimmunecheckpointinhibitors
AT salomaomarcelaa severediarrheainthesettingofimmunecheckpointinhibitors
AT gurudusuryakanthr severediarrheainthesettingofimmunecheckpointinhibitors

Ejemplares similares